Sputum Color Links to Bronchiectasis Severity
New clinical trial data correlates patient-reported sputum color with airway inflammation and disease severity.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe simple self-monitoring tools help you better manage your respiratory health?
Researchers have identified a link between patient-reported sputum color and the severity of bronchiectasis. Higher purulence levels in sputum were found to correlate with increased inflammatory activity and higher rates of pulmonary exacerbations.
Why it matters
Understanding this correlation provides clinicians with a simple metric to gauge lung inflammation. This may improve the monitoring of disease progression and the management of bronchiectasis exacerbations.
In the phase III ASPEN trial, 43.9% of participants reported mucopurulent sputum while 19.9% reported purulent sputum at baseline. The study evaluated patients over a 52-week treatment period using 10 mg and 25 mg dosages of brensocatib.
The players
ASPEN trial
This is a phase III clinical trial designed to evaluate the safety and efficacy of brensocatib in patients with bronchiectasis.
Chest 2026
This is an annual medical conference hosted by the American College of Chest Physicians to share research and clinical developments in pulmonary medicine.
The details
Patients in the study recorded their sputum color daily using the Bronchiectasis Exacerbation and Symptom Tool. Data analysis of 326 patients showed that greater sputum purulence is linked to higher levels of neutrophil serine protease activity and decreased lung function.
Timeline
Patients experienced at least two pulmonary exacerbations in the 12 months before screening.
The clinical trial treatment period lasted 52 weeks.
Findings were presented at the Chest 2026 conference in October 2026.
The Big Picture
The findings from the ASPEN trial represent a shift in how clinicians assess bronchiectasis, moving from subjective assessment to identifying biological markers of severity. This research updates clinical metrics established during the initial phases of the ASPEN trial.
Patients may find that tracking sputum color provides a more objective way to discuss their symptom progression with healthcare providers. This metric could lead to more timely medical interventions during the early stages of a pulmonary exacerbation.
The takeaway
Patients managing bronchiectasis should monitor changes in their sputum as a key indicator of lung health. Discussing these specific color changes with a doctor can help in identifying potential exacerbations before they become severe.
Further reading
For more information on the latest respiratory research, visit the World Asthma section.
Source note: This article includes information reported by Respiratory Therapy.
Live Poll
Do you believe simple self-monitoring tools help you better manage your respiratory health?
